Review
Copyright ©The Author(s) 2016.
World J Nephrol. May 6, 2016; 5(3): 258-273
Published online May 6, 2016. doi: 10.5527/wjn.v5.i3.258
Table 1 Standard of care therapeutic management
Drug classOn-target parameterOff-target parametersRef.
Antihypertensive
RAS blockersBP↓UAE↓, GTP↓, K+↑, AT1-7↑, cytokines↓, Klotho↑[53,54,56,69-82]
Aldosterone antagonistsBP↓UAE↓, K+[83-85]
K+ binders
BisacodylK+Diarrhea[86]
PatiromerK+[87]
Na zirconium cyclosilicateK+[88]
Blood sugar controlBlood sugar↓Progression↓[93-95]
HbA1c + 7Postpones need of Dx
Hypocholestrolemic
StatinsCholesterol↓, LDL↓Cardiovascular events↓[96]
Hypouricemic agents
AllpurinolUric acid↓Renal events↓, CV events↓[102,103]
FebuxoststUric acid↓CKD progression↓[104]
Sodium bicarbonateHCO3-↑, PH ↑Ptn catabolism↓, GFR decline↓[105,106]
Phosphate binders
Calcium basedP↓PTH↓, Vasc calc.↑[117-120]
SevelamerP↓PTH↓, stop vasc calc, Mortality↓, Uric acid↓, Cholesterol↓, LDL↓, inflammation↓ Cardiovascular events↓[121-131]
Lanthanum carbonateP↓PTH↓, stop vasc calc,[123-139]
Iron compoundsP↓Iron↑[140,141]
NicotinamideP↓TG↓, LDL↓, HDL↑[142-144]